Background In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause
mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral …

Background Insufficient data are available from single cohort studies to allow estimation of
the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral …

Understanding why some people establish and maintain effective control of HIV-1 and
others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-…

Background Hepatitis C virus (HCV) infection is highly prevalent among HIV-1-infected
individuals, but its contribution to the morbidity and mortality of coinfected patients who receive …

Background The efficacy of highly active antiretroviral therapy (HAART) in suppression of
HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in …

… Barbara Hasse, Bruno Ledergerber and Rainer Weber designed the study; Barbara … , Bruno
Ledergerber and Rainer Weber wrote the final version of the manuscript. Bruno Ledergerber …

Background Evidence on the effectiveness of highly active antiretroviral therapy (HAART)
for HIV-infected individuals is limited. Most clinical trials examined surrogate endpoints over …

Background: Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected
patients remains unclear. Objective: To assess the prevalence of HBV (assessed as HBsAg) …

ContextAcquired immunodeficiency syndrome–related opportunistic illnesses (OIs)
continue to occur after initiation of potent antiretroviral therapy in patients with human …

Background The SMART study was a trial of intermittent use of antiretroviral therapy (ART) (drug
conservation [DC]) versus continuous use of ART (viral suppression [VS]) as a strategy …